After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
Stocks Info
Ionis Pharmaceuticals Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Ionis Pharmaceuticals Inc is $5.35B. A total of 2.0 million shares were traded on the day, compared to an average of 1.75M shares.
In the most recent transaction, Hayden Michael R bought 15,000 shares of IONS for 31.86 per share on May 01 ’25. After the transaction, the Director now owns 50,219 company shares. In a previous transaction on Apr 16 ’25, Birchler Brian sold 680 shares at 28.37 per share. IONS shares that EVP, Corp and Development Ops owns now total 56,660.
Among the insiders who sold shares, Jenne Kyle disposed of 3,016 shares on Apr 16 ’25 at a per-share price of $28.36. This resulted in the EVP, Chf GL Pdt Str Ofcr holding 11,199 shares of IONS after the transaction. In another insider transaction, Baroldi Joseph sold 3,928 shares at $28.40 per share on Apr 16 ’25. Company shares held by the EVP, Chief Business Officer now total 31,926.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, IONS has a high of $52.34 and a low of $23.95.
As of this writing, IONS has an earnings estimate of $0.02 per share for the current quarter. EPS was calculated based on a consensus of 6.0 estimates, with a high estimate of $0.5 per share and a lower estimate of -$0.64.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. IONS’s latest balance sheet shows that the firm has $2.11B in Cash & Short Term Investments as of fiscal 2021. There were $1.25B in debt and $240.55M in liabilities at the time. Its Book Value Per Share was $2.99, while its Total Shareholder’s Equity was $771.74M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IONS is Buy with a score of 4.13.
